Roche’s multiple sclerosis blockbuster Ocrevus looks set to face new competition from a rival CD20 targeting antibody from TG Therapeutics – who are willing to offer their drug at a significant discount, once approved.
TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS
Filing Expected In Q3
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.
More from Anticancer
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.